These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31317423)

  • 1. Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study.
    Ceccarelli F; Lucchetti R; Perricone C; Spinelli FR; Cipriano E; Truglia S; Miranda F; Riccieri V; Di Franco M; Scrivo R; Alessandri C; Valesini G; Conti F
    Clin Rheumatol; 2019 Nov; 38(11):3145-3151. PubMed ID: 31317423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of Ultrasound in the Assessment of Oligoarticular Psoriatic Arthritis Subset: Results from Patients Treated with Apremilast.
    Lucchetti R; Ceccarelli F; Cipriano E; Perricone C; Spinelli FR; Alessandri C; Conti F
    Isr Med Assoc J; 2021 Jul; 23(7):412-415. PubMed ID: 34251122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
    Venerito V; Natuzzi D; Bizzoca R; Lacarpia N; Cacciapaglia F; Lopalco G; Iannone F
    Clin Exp Immunol; 2020 Aug; 201(2):200-204. PubMed ID: 32383167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).
    Nash P; Ohson K; Walsh J; Delev N; Nguyen D; Teng L; Gómez-Reino JJ; Aelion JA;
    Ann Rheum Dis; 2018 May; 77(5):690-698. PubMed ID: 29343507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.
    Kavanaugh A; Gladman DD; Edwards CJ; Schett G; Guerette B; Delev N; Teng L; Paris M; Mease PJ
    Arthritis Res Ther; 2019 May; 21(1):118. PubMed ID: 31077258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Keating GM
    Drugs; 2017 Mar; 77(4):459-472. PubMed ID: 28213862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis.
    Mavropoulos A; Zafiriou E; Simopoulou T; Brotis AG; Liaskos C; Roussaki-Schulze A; Katsiari CG; Bogdanos DP; Sakkas LI
    Rheumatology (Oxford); 2019 Dec; 58(12):2240-2250. PubMed ID: 31209492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis.
    Girolimetto N; Macchioni P; Tinazzi I; Costa L; Peluso R; Tasso M; Bascherini V; Addimanda O; Marchetta A; Possemato N; Salvarani C; McGonagle D; Scarpa R; Caso F
    Clin Rheumatol; 2020 Apr; 39(4):1157-1165. PubMed ID: 31302859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.
    Cutolo M; Myerson GE; Fleischmann RM; Lioté F; Díaz-González F; Van den Bosch F; Marzo-Ortega H; Feist E; Shah K; Hu C; Stevens RM; Poder A
    J Rheumatol; 2016 Sep; 43(9):1724-34. PubMed ID: 27422893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study.
    Strand V; Schett G; Hu C; Stevens RM
    J Rheumatol; 2013 Jul; 40(7):1158-65. PubMed ID: 23588944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal Study.
    Ceccarelli F; Cipriano E; Natalucci F; Perricone C; Olivieri G; Orefice V; Morello F; Alessandri C; Spinelli FR; Conti F
    Isr Med Assoc J; 2020 Jul; 22(7):415-419. PubMed ID: 33236565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apremilast retention rate in clinical practice: observations from an Italian multi-center study.
    Ariani A; Parisi S; Del Medico P; Farina A; Visalli E; Molica Colella AB; Lumetti F; Caccavale R; Scolieri P; Andracco R; Girelli F; Bravi E; Colina M; Volpe A; Ianniello A; Franchina V; Platè I; Di Donato E; Amato G; Salvarani C; Lucchini G; De Lucia F; Molica Colella F; Santilli D; Ferrero G; Marchetta A; Arrigoni E; Mozzani F; Foti R; Sandri G; Bruzzese V; Paroli M; Fusaro E; Becciolini A
    Clin Rheumatol; 2022 Oct; 41(10):3219-3225. PubMed ID: 35796847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety evaluation of apremilast for treating psoriatic arthritis.
    Busa S; Kavanaugh A
    Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations.
    Mease PJ; Gladman DD; Ogdie A; Coates LC; Behrens F; Kavanaugh A; McInnes I; Queiro R; Guerette B; Brunori M; Teng L; Smolen JS
    Arthritis Care Res (Hoboken); 2020 Jun; 72(6):814-821. PubMed ID: 31909868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of musculoskeletal ultrasound in predicting the response to JAK inhibitors: results from a monocentric cohort.
    Ceccarelli F; Spinelli FR; Garufi C; Mancuso S; Alessandri C; Di Franco M; Orefice V; Pacucci VA; Pirone C; Priori R; Riccieri V; Sili Scavalli A; Scrivo R; Truglia S; Conti F
    Clin Exp Rheumatol; 2022 May; 40(5):921-927. PubMed ID: 34251313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration.
    Girolimetto N; Costa L; Mancarella L; Addimanda O; Bottiglieri P; Santelli F; Meliconi R; Peluso R; Del Puente A; Macchioni P; Salvarani C; McGonagle D; Scarpa R; Caso F
    Clin Rheumatol; 2019 Mar; 38(3):903-911. PubMed ID: 30569440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients.
    Favalli EG; Conti F; Selmi C; Iannone F; Bucci R; D'Onofrio F; Carlino G; Santo L; Semeraro A; Zuccaro C; D'Angelo S; Atzeni F; Marino F; Monti S; Guidelli GM; Spinelli FR; Biggioggero M; Caporali R
    Clin Exp Rheumatol; 2020; 38(1):19-26. PubMed ID: 31074721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.